Vitamin D3 for Life

Live Enlightened

Article

Vitamin D supplementation and resistance to acute respiratory infections (Martineau et al., 2017): Full Evidence Review

Previous related pageVitamin D status and seasonal variation in common infections in adults: Full Evidence ReviewNext related pageVitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data: Full Evidence Review
Study at a glance

Can vitamin D supplements reduce respiratory infections?

Researchers asked whether vitamin D supplements reduced the chance of getting an infection in the breathing system. They combined information about each person from 25 trials involving more than 10,000 people. The trials included different ages and countries. People received vitamin D, a placebo with no active treatment, or no supplement.

Which groups had fewer infections with vitamin D?

The combined results showed a lower chance of having at least one respiratory infection among people given vitamin D. The reduction met the study’s statistical test. The strongest protection was seen in people with low vitamin D levels before treatment. Daily or weekly treatment showed more benefit than occasional large doses in the trials studied.

Why might protection from infection differ between people?

The trials differed in how long they lasted, the doses used and how infections were identified. Some trials were too small to give reliable answers about particular groups. The findings do not show that everyone would receive the same protection.

What can these results tell us about taking vitamin D?

The review supports a reduction in the infections measured under these trial conditions. It did not establish protection against a particular virus or explain exactly how immune cells were affected. It also did not test vaccine responses. These results do not provide a personal treatment or dosing plan.

Read the full article below ↓

Evidence from a single, verified study evaluated using a fixed, auditable study-page structure.

Study classification and identity

Study type
Individual participant data meta-analysis of randomized controlled trials

Parent study
Not applicable in this study

Ancillary study focus
System-level immune protection against acute respiratory infections

Exposure type
Randomized supplementation exposure

Intervention arms or exposure groups
Vitamin D supplementation versus placebo or no supplementation

Primary endpoint category
Clinical infectious disease outcomes

Clinical endpoints assessed
Incidence of acute respiratory infections

Study purpose and framing

This study assessed whether vitamin D supplementation reduces the risk of acute respiratory infections across diverse populations by pooling individual participant data from multiple randomized controlled trials.

The endpoint was framed as a measure of population-level immune resistance to common infectious stressors rather than as disease-specific therapeutic efficacy.

Why the primary measure is used as a biological marker

Acute respiratory infection incidence captures the integrated performance of innate and adaptive immune responses under repeated environmental pathogen exposure.

At the group level, reduced infection risk reflects enhanced immune robustness and resilience rather than isolated immunological pathway activation.

Measurement context relevant to this endpoint includes heterogeneity in exposure risk, baseline vitamin D status, and supplementation regimen across trials.

Study overview

Data were drawn from 25 randomized controlled trials including over 10,000 participants across multiple countries, age groups, and baseline vitamin D strata.

Participants receiving vitamin D supplementation were compared with control groups receiving placebo or no intervention.

Study design and measurement approach

Individual participant data were harmonized to allow consistent outcome definitions, covariate adjustment, and subgroup analyses across trials.

Key constraints include variability in dosing schedules, trial duration, and infection ascertainment methods.

Outcome hierarchy

Directly measured
Occurrence of at least one acute respiratory infection

Not measured
Cellular immune function, cytokine profiles, vaccine responses

Not inferable from this study
Individual clinical treatment recommendations or pathogen-specific immunity

Statistical analysis

A one-step individual participant data meta-analysis was used to estimate adjusted odds ratios for infection risk.

Models adjusted for age, sex, baseline vitamin D status, dosing frequency, and trial clustering.

Results

Vitamin D supplementation was associated with a statistically significant reduction in the risk of acute respiratory infections, with the strongest protective effect observed in individuals with low baseline vitamin D levels.

Daily or weekly dosing regimens showed greater benefit than intermittent high-dose bolus supplementation.

Measurement considerations and limitations

Outcome definitions and surveillance intensity varied between trials, potentially influencing absolute risk estimates.

Not all trials were powered for subgroup analyses, and residual confounding cannot be fully excluded.

Generalisability and population context

Findings apply most directly to general populations exposed to routine respiratory pathogens, particularly those with low baseline vitamin D status.

Generalisability to severe immunocompromise or specific viral pathogens is limited.

Mechanistic inference boundary

Mechanistic immune pathways were not directly tested in this analysis.

Observed effects are consistent with hypotheses of vitamin D: supported immune resilience but cannot confirm specific cellular mechanisms.

Interpretation within vitamin D physiology

The findings support a role for adequate vitamin D status in maintaining immune robustness under repeated infectious stressors.

For relevant physiology background, see Vitamin D and Immune Resilience.

Interpretation

This study supports an association between vitamin D supplementation and reduced susceptibility to acute respiratory infections at the population level.

Further work is required to define pathogen-specific effects and to link clinical outcomes with underlying immune mechanisms.

Primary source and publication details

Martineau AR, Jolliffe DA, Hooper RL, et al.

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.

BMJ. 2017.

DOI: Not applicable in this study

https://pubmed.ncbi.nlm.nih.gov/28202713/

Related reading

Original sources